QLT Obtains Orphan Drug Status for Drug to Treat Leber Congenital Amaurosis and Retinitis Pigmentosa

December 9, 2010

Biotech company, QLT Inc., announced earlier this week that the FDA has granted orphan drug designation for QLT091001, its oral synthetic retinoid for the treatment of Leber Congenital Amaurosis (LCA) and Retinitis Pigmentosa (RP).

Click here and here to read the relevant press releases.

 

 



Comments

Jump down to form below to submit your own comments

Trackback URL
http://eyedocnews.com/004247-qlt-obtains-orphan-drug-status-for-drugs-to-treat-leber-congenital-amaurosis-and-retinitis-pigmentosa/trackback/

Have insights to contribute? Please submit your comment below